The anti-PD1 moAbs, Pembrolizumab and nivolumab, as well as, the PD-L1 moAb, durvalumab, have been studied in the metastatic disease showing promising results in terms of PFS and OS [13]. The gene discussed is CD274; the disease is metastatic neoplasm.